Denali Therapeutics Inc. (DNLI) News
Filter DNLI News Items
DNLI News Results
|Event/Time||Symbol||Company||News Detail||Start||End||Change||POWR Rating|
|Loading, please wait...|
Latest DNLI News From Around the Web
Below are the latest news stories about Denali Therapeutics Inc that investors may wish to consider to help them evaluate DNLI as an investment opportunity.
Fourteen biotechs have gone public in 2020, just three fewer than for the same period last year Continue reading...
Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity
Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly created dual role as both CEO-Partner of Flagship Pioneering and Chief Executive Officer of Cellarity.
Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine
Denali’s “Transport Vehicle” technology enables broad distribution and improved exposure levels of therapeutic proteins throughout the brainClinical proof of concept data with.
Denali Therapeutics Inc. (DNLI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Analyst Estimates: Here's What Brokers Think Of Denali Therapeutics Inc. (NASDAQ:DNLI) After Its First-Quarter Report
Investors in Denali Therapeutics Inc. (NASDAQ:DNLI) had a good week, as its shares rose 9.6% to close at US$23.89...
Denali Therapeutics Inc (DNLI) delivered earnings and revenue surprises of 3.51% and -39.19%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Denali Therapeutics Reports First Quarter 2020 Financial Results and Provides COVID-19 Response Update
SOUTH SAN FRANCISCO, May 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio…
Analysts Estimate Denali Therapeutics Inc. (DNLI) to Report a Decline in Earnings: What to Look Out for
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays
In the span of eight days last month, CytomX Therapeutics Inc. landed a collaboration with Astellas Pharma and captured a $40 million milestone payment from AbbVie Inc. as it preps for a mid-stage cancer clinical trial. “It’s a challenging time for our industry,” said CytomX President and CEO Sean McCarthy.